BR112016008331A2 - composição para tratar e prevenir hiperplasia prostática benigna - Google Patents

composição para tratar e prevenir hiperplasia prostática benigna

Info

Publication number
BR112016008331A2
BR112016008331A2 BR112016008331A BR112016008331A BR112016008331A2 BR 112016008331 A2 BR112016008331 A2 BR 112016008331A2 BR 112016008331 A BR112016008331 A BR 112016008331A BR 112016008331 A BR112016008331 A BR 112016008331A BR 112016008331 A2 BR112016008331 A2 BR 112016008331A2
Authority
BR
Brazil
Prior art keywords
benign prostatic
prostatic hyperplasia
composition
treating
treat
Prior art date
Application number
BR112016008331A
Other languages
English (en)
Other versions
BR112016008331B1 (pt
Inventor
Jae Kim Sang
Original Assignee
Gemvax & Kael Co Ltd
Jae Kim Sang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemvax & Kael Co Ltd, Jae Kim Sang filed Critical Gemvax & Kael Co Ltd
Publication of BR112016008331A2 publication Critical patent/BR112016008331A2/pt
Publication of BR112016008331B1 publication Critical patent/BR112016008331B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Abstract

resumo “composição para tratar e prevenir hiperplasia prostática benigna” a presente invenção diz respeito a uma composição para tratar e prevenir hiperplasia prostática benigna, e um método para tratar hiperplasia prostática be-nigna usando a mesma. mais especificamente, a presente invenção diz respeito a uma composição compreendendo peptídeos derivados de telomerase para efetiva-mente tratar e prevenir hiperplasia prostática benigna e um método para tratar hiper-plasia prostática benigna usando os mesmos. a composição compreendendo o pep-tídeo de acordo com a presente invenção exibe excelente eficácia no tratamento e prevenção de hiperplasia prostática benigna.
BR112016008331-8A 2013-10-23 2014-10-23 Composição para tratar e prevenir hiperplasia prostática benigna (bhp) e uso da dita composição para tratar e prevenir bhp BR112016008331B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130126666 2013-10-23
KR10-2013-0126666 2013-10-23
PCT/KR2014/010035 WO2015060673A1 (ko) 2013-10-23 2014-10-23 전립선 비대증 치료 및 예방용 조성물

Publications (2)

Publication Number Publication Date
BR112016008331A2 true BR112016008331A2 (pt) 2017-09-26
BR112016008331B1 BR112016008331B1 (pt) 2023-01-31

Family

ID=52993192

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016008331-8A BR112016008331B1 (pt) 2013-10-23 2014-10-23 Composição para tratar e prevenir hiperplasia prostática benigna (bhp) e uso da dita composição para tratar e prevenir bhp

Country Status (12)

Country Link
US (1) US9572858B2 (pt)
EP (1) EP3061459B1 (pt)
JP (1) JP6382972B2 (pt)
KR (2) KR102166544B1 (pt)
CN (2) CN105899224B (pt)
AU (1) AU2014337805B2 (pt)
BR (1) BR112016008331B1 (pt)
CA (1) CA2926183C (pt)
ES (1) ES2773296T3 (pt)
PH (1) PH12016500651B1 (pt)
RU (2) RU2661596C2 (pt)
WO (1) WO2015060673A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167299A1 (en) 2012-05-11 2013-11-14 Kael-Gemvax Co., Ltd. Anti-inflammatory peptides and composition comprising the same
EP2875824B1 (en) 2012-05-11 2018-01-03 KAEL-GemVax Co.,Ltd Composition for preventing or treating cachexia
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US9907838B2 (en) 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
RU2677277C2 (ru) 2013-06-07 2019-01-16 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
KR20160039152A (ko) 2013-06-21 2016-04-08 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
US10034922B2 (en) 2013-11-22 2018-07-31 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
JP6367950B2 (ja) 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー，リミティド 前立腺癌治療用組成物
WO2015156649A1 (ko) 2014-04-11 2015-10-15 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
CN107405380B (zh) 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
KR102638286B1 (ko) 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
KR20180123512A (ko) 2016-04-07 2018-11-16 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN108079277A (zh) * 2018-01-17 2018-05-29 江苏优曦特斯生物制品有限公司 一种治疗前列腺增生的中药组合物及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
ATE361099T1 (de) 1997-05-15 2007-05-15 Chugai Pharmaceutical Co Ltd Heilmittel für kachexie
CA2294782A1 (en) 1997-07-01 1999-01-14 Cambia Biosystems Llc Vertebrate telomerase genes and proteins and uses thereof
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
IL132406A0 (en) 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
KR100801121B1 (ko) 2001-04-10 2008-02-05 니뽄 신야쿠 가부시키가이샤 만성 관절 류마티즘 치료제
JP4502580B2 (ja) 2001-05-16 2010-07-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 敗血症の治療または予防のためのｉｌ−１８阻害剤の使用
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
KR20050020987A (ko) 2002-06-12 2005-03-04 바이오겐 아이덱 엠에이 인코포레이티드 아데노신 수용체 길항제를 사용하여 허혈 재관류 손상을치료하는 방법
KR20050040517A (ko) 2003-10-29 2005-05-03 주식회사 오리엔트 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
ES2366380T3 (es) * 2005-06-14 2011-10-19 Protox Therapeutics Incorporated Método para el tratamiento o prevención de hiperplasia prostática benigna utilizando proteínas formadoras de poros modificadas.
JP2009519033A (ja) 2005-12-16 2009-05-14 ディアト 核酸を細胞に送達するための細胞貫通ペプチド結合体
JP5295785B2 (ja) 2006-02-20 2013-09-18 エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション 細胞膜透過性ペプチド
KR20090103957A (ko) 2007-01-29 2009-10-01 주식회사 프로셀제약 신규한 거대분자 전달 도메인 및 이의 동정 방법 및 용도
JP2010532484A (ja) 2007-06-29 2010-10-07 コレロジック システムズ，インコーポレイテッド 卵巣癌のための予測マーカー
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2009054996A2 (en) 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
AT506095A1 (de) * 2007-12-03 2009-06-15 Volopharm Gmbh Verwendung von proteasen
GB2455539B (en) 2007-12-12 2012-01-18 Cambridge Entpr Ltd Anti-inflammatory compositions and combinations
HUE030984T2 (en) * 2008-06-16 2017-06-28 Mediolanum Farm S P A Antitumor immunotherapy
ES2334315B1 (es) 2008-07-29 2011-02-28 Universitat Pompeu Fabra Peptidos con capacidad de penetracion celular y sus usos.
JP5337809B2 (ja) 2008-09-22 2013-11-06 日清ファルマ株式会社 抗炎症性ペプチド
KR101169030B1 (ko) 2009-01-21 2012-07-26 애니젠 주식회사 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
CN102428096B (zh) 2009-05-20 2015-03-25 东丽株式会社 细胞膜通透性肽
KR20110057049A (ko) 2009-11-23 2011-05-31 박의신 기능성 전립선염 치료제
KR20110062943A (ko) 2009-12-04 2011-06-10 주식회사종근당 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제
DK2536830T3 (da) * 2010-02-16 2019-10-21 Ultimovacs As Polypeptider
KR101263212B1 (ko) 2010-05-28 2013-05-10 성신여자대학교 산학협력단 신규한 세포막 투과성 펩타이드 및 그의 용도
WO2011150493A1 (en) 2010-05-30 2011-12-08 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for antimicrobials
MX354187B (es) * 2010-07-15 2018-02-16 Oleg Iliich Epshtein Composicion farmaceutica combinada y metodos para el tratamiento de los trastornos del sistema genitourinario.
KR101348284B1 (ko) 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
WO2013135266A1 (en) * 2012-03-12 2013-09-19 Gemvax As Treatment of non-small cell lung carcinoma by active immunotherapy
WO2013167299A1 (en) 2012-05-11 2013-11-14 Kael-Gemvax Co., Ltd. Anti-inflammatory peptides and composition comprising the same
EP2875824B1 (en) 2012-05-11 2018-01-03 KAEL-GemVax Co.,Ltd Composition for preventing or treating cachexia
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
KR102362341B1 (ko) 2012-09-19 2022-02-14 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
ES2743919T3 (es) 2012-09-19 2020-02-21 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
ES2758451T3 (es) 2012-09-19 2020-05-05 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
US9907838B2 (en) 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
RU2677277C2 (ru) 2013-06-07 2019-01-16 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
KR20160039152A (ko) * 2013-06-21 2016-04-08 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법

Also Published As

Publication number Publication date
KR102166544B1 (ko) 2020-10-16
RU2661596C2 (ru) 2018-07-17
PH12016500651A1 (en) 2016-05-30
AU2014337805B2 (en) 2018-03-15
RU2016113055A (ru) 2017-11-28
US9572858B2 (en) 2017-02-21
EP3061459A1 (en) 2016-08-31
PH12016500651B1 (en) 2016-05-30
CN110755599A (zh) 2020-02-07
KR20160121608A (ko) 2016-10-19
EP3061459B1 (en) 2019-12-11
JP2016535740A (ja) 2016-11-17
CA2926183A1 (en) 2015-04-30
RU2683649C1 (ru) 2019-04-01
WO2015060673A1 (ko) 2015-04-30
ES2773296T3 (es) 2020-07-10
KR101691479B1 (ko) 2017-01-02
AU2014337805A1 (en) 2016-04-28
RU2016113055A3 (pt) 2018-03-06
US20160250279A1 (en) 2016-09-01
KR20150140730A (ko) 2015-12-16
JP6382972B2 (ja) 2018-08-29
CA2926183C (en) 2018-07-03
CN105899224B (zh) 2019-12-13
BR112016008331B1 (pt) 2023-01-31
CN105899224A (zh) 2016-08-24
EP3061459A4 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
BR112016008331A2 (pt) composição para tratar e prevenir hiperplasia prostática benigna
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
CL2018000429A1 (es) Moduladores de la expresión de kras
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
PH12015502028A1 (en) Ido inhibitors
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
BR112017011900A2 (pt) tratamento de ataques com fosfatase alcalina recombinante
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201491500A1 (ru) Способы лечения фиброза
EA201991650A1 (ru) Способы лечения неврологических расстройств
JOP20190241B1 (ar) مستحضرات رذاذ إبينيفرين
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
EA201791933A1 (ru) Ингибирование активности olig2
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
EA201591480A1 (ru) Способы лечения дискинезии и сопутствующих расстройств
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
EA201990930A1 (ru) Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO 870170033089 DE18/05/2017, COM BASE NO ART. 219, II DA LEI DA PROPRIEDADE INDUSTRIAL, UMA VEZ QUE O INTERESSADO E PESSOA JURIDICA E NAO PODE REQUERER PELO MOTIVO EXPOSTO, CONFORME O ART. 2O, I, D DA RESOLUCAO 151/2015.

B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2014, OBSERVADAS AS CONDICOES LEGAIS